<DOC>
	<DOCNO>NCT02575456</DOCNO>
	<brief_summary>A Single-Center , Randomized , Blind , Phase II Clinical Trial Evaluate Safety Immunogenicity Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine ( Ad5-EBOV ) Healthy Adults Aged Between 18 50 year Sierra Leone .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 18 50 year Able understand content inform consent sign informed consent Able willing complete seclude study process whole study followup period ( 6 month ) . Negative HIV diagnostic blood test day enrollment Axillary temperature ≤37.0°C day enrollment Nonpregnant females negative result urine pregnancy test day enrollment General good health establish medical history physical examination . Infected Ebola virus ( inquiry ) Vaccination Ebola vaccine ( inquiry ) HIV infection serious immunodeficiency disease ( inquiry ) Allergic history vaccination drug , allergic ingredient Ad5EBOV , mannitol Family history brain mental disease Woman pregnant breastfeed Any acute fever disease infection last 7 day Major congenital defect wellcontrolled chronic illness Asplenia functional asplenia Platelet disorder bleed disorder Faint sight blood needle . Prior administration immunodepressant corticosteroid , antianaphylaxis treatment , cytotoxic treatment last 6 month Prior administration research medicine last 1 month Prior administration attenuate vaccine ( ) last one month Prior administration inactivate vaccine ( ) last 14 day Any condition opinion investigator may interfere participant ' compliance evaluation study objective</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>